Joint with: Obesity Therapeutics: Unlocking Benefits and Minimizing Side Effects
Cardiometabolism in Health and Disease
January 1-4, 2026 | Location to be Determined
Scientific Organizers:
Daniel P. Kelly, Rong Tian and William C. Sessa
In Person
On Demand
January 1-4, 2026 | Location to be Determined
Scientific Organizers:
Daniel P. Kelly, Rong Tian and William C. Sessa
Available Formats:
In Person
On Demand
Supported by the Directors' Fund
Available Formats: = In Person = On Demand
Thursday, January 1, 2026
Booking Function
Merchandise Options
Registration Options
Registration
4:00–8:00 PM
Welcome Mixer
6:00–8:00 PM
Friday, January 2, 2026
Breakfast
7:00–8:00 AM
Welcome and Keynote Address
8:00–9:00 AM
Jens Juul Holst †, University of Copenhagen the Panum Institute
GLP-1 and Multi-Agonist Incretins: Clinical Impact- Hits and Misses
GLP-1 and Multi-Agonist Incretins: Clinical Impact- Hits and Misses
Beyond Weight Loss: Applications of Obesity Medications to Other Indications (Joint)
9:00–11:15 AM
Rachel J. Roth Flach †, Pfizer Inc.
Targeting Metabolism for HFpEF
Targeting Metabolism for HFpEF
Susan Quaggin †, Northwestern University
A United Vision for Kidney and Cardiovascular Disease Treatment
A United Vision for Kidney and Cardiovascular Disease Treatment
James Trevaskis, Eli Lilly
Incretins for MASH Treatment
Incretins for MASH Treatment
Short Talk(s) Chosen from Abstracts
Coffee Break
9:30–9:50 AM
On Own for Lunch
11:15–5:00 PM
Poster Setup
11:15–1:00 PM
Poster Viewing
1:00–10:00 PM
Workshop 1: Emerging Therapies, Lifestyle Interventions and AI Approaches
1:00–10:00 PM
Short Talk(s) Chosen from Abstracts
Coffee Available
4:30–5:00 PM
Metabolic Origins of Heart Health and Disease
5:00–7:00 PM
Daniel P. Kelly, University of Pennsylvania
Modulating Cardiac Maturation in the Failing Heart
Modulating Cardiac Maturation in the Failing Heart
Catherine A. Makarewich †, Cincinnati Children's Hospital Medical Center
Microproteins as Targets in the Diseased Heart
Microproteins as Targets in the Diseased Heart
David A. Kass †, Johns Hopkins Hospital
Integrated OMIC and Physiologic Interrogation of HFpEF
Integrated OMIC and Physiologic Interrogation of HFpEF
Short Talk(s) Chosen from Abstracts
Social Hour with Lite Bites
7:00–8:00 PM
Posters
7:30–10:00 PM
Saturday, January 3, 2026
Breakfast
7:00–8:00 AM
Metabolic Contributions to Vascular Health and Disease
8:00–11:00 AM
William C. Sessa, Pfizer
Probing Trans-Vascular Lipid Trafficking
Probing Trans-Vascular Lipid Trafficking
Katrien De Bock †, Swiss Federal Institute of Technology
Metabolic Determinants of Angiogenesis in Disease States
Metabolic Determinants of Angiogenesis in Disease States
Yajaira Suarez †, Yale School of Medicine
Endothelial Metabolic Re-Wiring
Endothelial Metabolic Re-Wiring
Zoltan Arany †, University of Pennsylvania
Metabolic Determinants of Vascular Function
Metabolic Determinants of Vascular Function
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
On Own for Lunch
11:00–5:00 PM
Poster Setup
11:00–1:00 PM
Poster Viewing
1:00–10:00 PM
Panel Discussion: SGLT2 and GLP-1: Potential Mechanisms of Cardioprotective Actions
1:30–3:15 PM
Career Roundtable (Joint)
3:30–4:30 PM
Coffee Available
4:30–5:00 PM
Mitochondria and Cardiometabolic Disease
5:00–7:00 PM
Rong Tian, University of Washington
Mitochondria in HFpEF
Mitochondria in HFpEF
E. Dale Abel †, David Geffen School of Medicine and UCLA Health
Mitochondrial Derangements in the Diabetic Heart
Mitochondrial Derangements in the Diabetic Heart
Yibin Wang †, Duke-NUS, Singapore
Branched-Chain Amino Acid Metabolism in the Failing Heart
Branched-Chain Amino Acid Metabolism in the Failing Heart
Short Talk(s) Chosen from Abstracts
Social Hour with Lite Bites
7:00–8:00 PM
Posters
7:30–10:00 PM
Sunday, January 4, 2026
Breakfast
7:00–8:00 AM
Emerging Therapies for Obesity and Cardiometabolic Diseases (Joint)
8:00–11:00 AM
Matthias H. Tschöp †, Helmholtz Munich
Dual and Triple Co-Agonists: Past, Present and Future
Dual and Triple Co-Agonists: Past, Present and Future
Elisabeth Björk †, AstraZeneca
SLGT-1: Risks and Opportunities
SLGT-1: Risks and Opportunities
Thomas Alexander Lutz †, University of Zürich
Amylin Combinations as Obesity Therapeutics
Amylin Combinations as Obesity Therapeutics
Murielle M. Véniant-Ellison †, Amgen Inc.
GLP-1 Receptor Agonist and GIP Receptor Antagonists for Obesity Treatment
GLP-1 Receptor Agonist and GIP Receptor Antagonists for Obesity Treatment
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
On Own for Lunch
11:00–5:00 PM
Workshop 2: Next-Gen Metabolomics (Single Cell, Spatial Mass-Spect Imaging) (Joint)
2:30–4:30 PM
Short Talk(s) Chosen from Abstracts
Coffee Available
4:30–5:00 PM
Environmental and Social Modulators of CV Health and Disease
5:00–6:45 PM
Martin E. Young †, University of Alabama at Birmingham
Circadian Control of the Heart in Health and Disease
Circadian Control of the Heart in Health and Disease
Danica Chen †, University of California, Berkeley
Aging and Cardiovascular Health
Aging and Cardiovascular Health
Gary H. Gibbons †, NHLBI, National Institutes of Health
Social Determinants of Cardiometabolic Diseases
Social Determinants of Cardiometabolic Diseases
Short Talk(s) Chosen from Abstracts
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
6:45–7:00 PM
Social Hour with Lite Bites
7:00–8:00 PM
Cash Bar
8:00–11:00 PM
Entertainment
8:00–11:00 PM
Monday, January 5, 2026
Departure
12:00–11:59 PM
Subscribe for Updates